UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/925,192	08/09/2001	Dan W. Denney JR.	GENITOPE-06493	5113
MEDLEN & C	7590 02/07/2007 CARROLL, LLP	EXAMINER		
Suite 350 101 Howard Street San Francisco, CA 94105			YAEN, CHRISTOPHER H	
			ART UNIT	PAPER NUMBER
,			1643	
SHORTENED STATUTOR	RY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
3 MC	ONTHS	02/07/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		Application No.	Applicant(s)
Office Action Summary		09/925,192	DENNEY, DAN W.
		Examiner	Art Unit
		Christopher H. Yaen	1643
Period fo	The MAILING DATE of this communication apport	pears on the cover sheet with the c	orrespondence address
WHI(- Exte after - If NO - Failt Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING Discions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. O period for reply is specified above, the maximum statutory period vire to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status	•		
	Responsive to communication(s) filed on <u>17 Jac</u> This action is FINAL . 2b) This Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro	
Disposit	ion of Claims		
5)□ 6)⊠ 7)□ 8)□ Applicat i	Claim(s) 35-39 is/are pending in the application 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) 35-39 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or ion Papers The specification is objected to by the Examine The drawing(s) filed on is/are: a) according a content of the specification is objected to by the examine the drawing(s) filed on is/are: a) according to the specification is objected to by the examine the drawing(s) filed on is/are: a) according to the specification is objected to by the examine the drawing(s) filed on is/are: a) according to the specification is objected to by the examine the drawing(s) filed on is/are: a) according to the specification is objected to by the examine the drawing(s) filed on is/are: a) according to is/are: a) is/are: a) according to is/are: a) according to is/are: according to is/are: a)	wn from consideration. r election requirement. r.	Examiner.
	Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Ex	drawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).
Priority ι	ınder 35 U.S.C. § 119		
a)	Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureausee the attached detailed Office action for a list	s have been received. s have been received in Application ity documents have been receive I (PCT Rule 17.2(a)).	on No d in this National Stage
2) 🔲 Notic 3) 🔲 Inforr	t(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	4) Interview Summary (Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:	te

Art Unit: 1643

DETAILED ACTION

Re: Denney et al

The amendment filed 11/17/2006 is acknowledged and entered into the record.

Accordingly, claims 1-34 are canceled without prejudice or disclaimer.

Claims 35-39 are pending and examined on the merits.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim Rejections Maintained - 35 USC § 103

The rejection of claims 35-39 under 35 USC § 103(a) as being obvious over is maintained for the reasons of record. Applicant argues that the combination of the references fail to teach each and every limitation of the claimed method, that the references teaches away from making such combinations, and there is no expectation of success. Applicant's arguments have been carefully considered but are not deemed persuasive to overcome the rejection of record.

When given the broadest reasonable interpretation, a cell expressing a multivalent composition for active immunotherapy encompasses using the cell to produce a soluble multivalent composition. The following rejection applies to using the recombinant cells to secrete the soluble multivalent composition.

Applicant argues that none of the references teach or suggest individual transformed cells or clones which express combinations of variant VH or VL sequences as recited by the present claims. This has been considered but not found persuasive.

The instant claims require the isolation of a transformed cell comprising at least one Vh region and at least two VI regions; at least two VH regions and at least one VL region; at least two VH regions and at least two VH regions and at least two VH regions and at least two VL regions differ by at least one idiotope.

Page 3

The claim does not require the scrambling of VH regions and VL regions, so as to produce VH regions and VL regions that do not associate in the same manner as that originally found in the patient. The claim only requires that the multivalent composition of expressed VH and VL represent at least one different idiotope. A multivalent composition comprising secreted lg reflecting the idiotypic variation found in the patient would be the same as that claimed irregardless of whether or not it came from a single clone expressing the alternate idiotope or a multitude of different clones encompassing the alternate idiotope. Thus, it is concluded that Embleton et al does not teach against the instant claims as there is ample motivation to include a multitude of different clones processed by the method of Embleton et al in order to provide a spectrum of clones reflecting the diversity of the lg found in the patient having quasi-clonal B cell lymphoma.

Conclusion

No claim is allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Art Unit: 1643

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher H. Yaen whose telephone number is 571-272-0838. The examiner can normally be reached on Monday-Friday 9-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms, Ph.D. can be reached on 571-272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Christopher Yaen Art Unit 1643 January 31, 2007

CHRISTOPHER H. YAEN PRIMARY EXAMINER